GL Globe Life
High-return niche insurer and steady buyback compounder; still priced above normalized value despite the pullback.
The story
Globe Life is a niche life and supplemental health insurer selling low-face-value policies to middle-income households through captive agencies, with steady premium growth (~4.7% CAGR) and operating margins rising from 22.8% to 26.3%. Trailing ROE of 19.8% is inflated because unrealized bond losses (AOCI) depress reported book, so the underlying return is closer to the mid-teens. The balance sheet is conservative, liability-driven and long-duration, and life underwriting is not very cyclical. The ongoing overhang is agency-practice scrutiny and the regulatory probes that followed it.
Drivers are unchanged from October: margin gains and a 19.8% trailing ROE support 17%, but much of that headline comes from an AOCI-shrunken book rather than better economics, so I won't chase the peak. Heavy buybacks keep book growth modest, and the terminal 4% stays below the 5.1% risk-free rate. The roughly 6% fall in the share price is market movement, not new fundamental information.
Value drivers
| Return on equity (normalized) | 17.0% |
| Book-value growth (Y1) | 6.0% |
| Terminal book growth | 4.0% |
| Beta | 0.95 |
| Failure probability | 2.0% |
| Cost of equity | 9.4% |
Valuation bridge
| PV of excess returns | 2.33B |
| PV of terminal excess | 1.48B |
| Equity value | 9.59B |
| ÷ shares → per share | $127.11 |
Projected excess returns on equity
| Yr | Book equity | ROE | Excess return | PV |
|---|---|---|---|---|
| 1 | 5.97B | 17.0% | 455.38M | 416.34M |
| 2 | 6.33B | 16.4% | 443.14M | 370.41M |
| 3 | 6.70B | 15.8% | 426.90M | 326.24M |
| 4 | 7.07B | 15.1% | 406.45M | 283.98M |
| 5 | 7.45B | 14.5% | 381.60M | 243.76M |
| 6 | 7.83B | 13.9% | 352.20M | 205.69M |
| 7 | 8.21B | 13.3% | 318.12M | 169.86M |
| 8 | 8.59B | 12.6% | 279.28M | 136.33M |
| 9 | 8.98B | 12.0% | 235.61M | 105.16M |
| 10 | 9.36B | 11.4% | 187.12M | 76.35M |
Key risks
- Agency misconduct allegations and regulatory or legal action damaging recruiting and sales at American Income
- Higher policy lapses or worse mortality/morbidity in health lines
- Large AOCI swings that distort book value and capital flexibility if rates move sharply
Catalysts
- Resolution of DOJ/SEC inquiries removing the governance discount
- Continued buybacks and margin expansion lifting EPS and per-share book